Defining success in clinical trials - Profiling pregabalin, the newest AED

European Journal of Neurology, Supplement

Volumn 12, Issue 4, 2005, Pages 12-21

  Ryvlin, Philippe ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Adjunctive therapy; Anti epileptic drugs; Clinical trials; Efficacy; Partial seizures; Pregabalin; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO; PREGABALIN;

AMBLYOPIA; ASTHENIA; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FOCAL EPILEPSY; HEADACHE; HUMAN; INFECTION; INJURY; PAIN; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREMOR; WEIGHT GAIN;

EID: 27744435940     PISSN: 14710552     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01327.x     Document Type: Conference Paper

References (19)

1. Arroyo S, Anhut H, Kugler AR et al. (2004). Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45:20-27.
2. Baulac M, Spiegel K, Lee CM, Barrett JA (2004). Long-term seizure freedom in patients with partial seizures treated with add-on pregabalin: update of an ongoing analysis of four open-label trials. Epilepsia 45(Suppl. 3):154. Poster (#P396) presented at the 6th European Congress on Epileptology, Vienna, Austria, May 30-June 3, 2004.
3. Ben-Menachem E (2004). Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6):13-18.
4. Beydoun A, Uthman BM, Kugler AR et al. (2005). Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64:475-480.
5. Brodie MJ (2004). Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45(Suppl. 6):19-27.
6. Brodie MJ, Wilson EA, Wesche DL et al. (2005). Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46:1407-1413.
7. Committee for Proprietary Medicinal Products (2000). Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. CHMP/EWP/566/98rev1. London. Available at: http://www.emea.eu.int/ pdfs/human/ewp/056698en.pdf (accessed on 30 September 2004).
8. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH (1999). New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40:590-600.
9. 3H]-norepinephrine release from rat neocortical slices. Synapse 45:171-190.
10. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA (2005). Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia, in press.
11. Ferrendelli JA (2001). Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 42(Suppl. 4):28-30.
12. French JA (2001). Proof of efficacy trials: endpoints. Epilepsy Res 45:53-56.
13. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA (2003). Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60:1631-1637.
14. International Council on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (1994). Guideline for industry: dose-response information to support drug registration. ICH-E4. Federal Register.
15. Mohanraj R, Brodie MJ (2003). Measuring the efficacy of antiepileptic drugs. Seizure 12:413-443.
16. Perucca E (2002). What can we learn from clinical trials of anticonvulsant drugs in epilepsy? Eur J Pain 6(Suppl. A):35-44.
17. Perucca E, Robbins JL, Kugler AR et al. (2002). Pregabalin demonstrates anticonvulsant activity onset by second day. Epilepsia 43(Suppl. 8):1-227.
18. Pledger G (2001). Proof of efficacy trials: choosing the dose. Epilepsy Res 45:23-28.
19. Taylor CP, Vartanian MG (1997). Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia 38(Suppl. 8):35.